AU · rank #6 · 2026-09-08
INSM
NASDAQ · $27.58B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.062 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.67 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.186 |
| Analyst upside Consensus target $200.18 | +58.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +40.93% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.81 |
| Gross margin TTM | +83.5% |
| 52w high | $212.75 |
| Market cap (USD) | $27.58B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Insmed is a commercial-stage rare/respiratory disease biopharma whose growth is now anchored by BRINSUPRI, a recently launched product generating $309M in Q2 2026 alone alongside the established ARIKAYCE franchise.
Rationale
The analyst_upside_pct of 58.5% is credible given a 91% Q2 EPS beat, raised full-year guidance to $1.25–$1.4B, strong revision breadth (81% agreement, 10 net upward revisions in 30 days), and a near-unanimous Strong Buy consensus from 17 analysts with targets up to $263—all pointing to a Street that is still catching up to BRINSUPRI's commercial ramp.
Material risks
- 1BRINSUPRI launch concentration risk—with ~73% of Q2 revenue from a single newly launched product, any safety signal, label restriction, or competitive entrant targeting the same indication would collapse the revenue thesis before it matures.
- 2High target dispersion (37%) and zero insider buying over 90 days suggest meaningful uncertainty around peak sales estimates and insider conviction is absent despite the bullish Street narrative.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.